- Sections
- C - Chimiemétallurgie
- C12N - Micro-organismes ou enzymescompositions les contenantculture ou conservation de micro-organismestechniques de mutation ou de génétiquemilieux de culture
- C12N 5/16 - Cellules animales
Détention brevets de la classe C12N 5/16
Brevets de cette classe: 1236
Historique des publications depuis 10 ans
|
94
|
109
|
109
|
87
|
74
|
65
|
58
|
41
|
29
|
20
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 20924 |
16 |
| Regeneron Pharmaceuticals, Inc. | 4822 |
16 |
| F. Hoffmann-La Roche AG | 7792 |
14 |
| Amgen Inc. | 4486 |
13 |
| The Trustees of the University of Pennsylvania | 4441 |
11 |
| Dana-Farber Cancer Institute, Inc. | 2677 |
11 |
| The University of British Columbia | 1557 |
11 |
| Board of Regents, The University of Texas System | 6177 |
10 |
| CRISPR Therapeutics AG | 372 |
10 |
| Crystal Bioscience Inc. | 89 |
10 |
| Abbvie Inc. | 1807 |
9 |
| The Board of Trustees of the Leland Stanford Junior University | 6722 |
8 |
| CHO Plus, Inc. | 17 |
8 |
| Novartis AG | 10172 |
7 |
| Genentech, Inc. | 4147 |
7 |
| The Board of Trustees of the University of Illinois | 2752 |
7 |
| ImmunoGen, Inc. | 376 |
7 |
| Kyoto University | 2941 |
7 |
| Pierre Fabre Medicament | 512 |
7 |
| The Board of Regents of the University of Texas System | 2312 |
7 |
| Autres propriétaires | 1040 |